Multiple Myeloma Treatment
Edanur Tekin1, Özge Çağlar1,2, Elif Özyılmaz3, Oytun Erbaş1,4
1ERBAS Institute of Experimental Medicine, Illinois, USA & Gebze, Turkey
2Department of Chemistry, Selçuk University, Faculty of Science, Konya, Turkey
3Department of Biochemistry, Selçuk University, Faculty of Science, Konya, Turkey
4Department of Physiology, Medical Faculty of Demiroğlu Bilim University, Istanbul, Turkey
Keywords: Multiple myeloma, myeloma, treatment and drugs.
Abstract
Multiple myeloma (MM) is a cancer that begins in the plasma cells (PC) and progresses to the bone marrow. It is a recurring disease, as no definitive solution can be found despite the drugs and treatments applied. Therefore, correct care is vital for sick individuals. MM is known to be a disease that most commonly affects individuals between the ages of 40 and 60 and rarely occurs in individuals under the age of 40. Exposure to certain chemicals and radiation, weakened immune systems and viruses, are among the factors that cause disease. This review is aimed to explain the drugs and treatments developed for the treatment of MM.
Cite this article as: Tekin E, Çağlar Ö, Özyılmaz E, Erbaş O. Multiple Myeloma Treatment. JEB Med Sci 2021;2(2):206-210.
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.